Comparative Pharmacology
Head-to-head clinical analysis: PROVENTIL HFA versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVENTIL HFA versus SEREVENT.
PROVENTIL-HFA vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist